These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32930115)

  • 1. Definitive concurrent chemoradiotherapy outcomes in Stage IIIB nonsmall cell lung cancer patients younger than 45 years: A retrospective analysis of 145 patients.
    Topkan E; Guler OC; Ozdemir Y
    J Cancer Res Ther; 2020; 16(4):757-763. PubMed ID: 32930115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of weight change during the course of concurrent chemoradiation therapy on outcomes in stage IIIB non-small cell lung cancer patients: retrospective analysis of 425 patients.
    Topkan E; Parlak C; Selek U
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):697-704. PubMed ID: 24035331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of overall concurrent chemoradiotherapy duration on survival outcomes of stage IIIB/C non-small-cell lung carcinoma patients: Analysis of 956 patients.
    Topkan E; Ozdemir Y; Kucuk A; Besen AA; Mertsoylu H; Sezer A; Selek U
    PLoS One; 2019; 14(7):e0218627. PubMed ID: 31329602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of pretreatment Glasgow prognostic score in stage IIIB geriatric non-small cell lung cancer patients undergoing radical chemoradiotherapy.
    Topkan E; Bolukbasi Y; Ozdemir Y; Besen AA; Mertsoylu H; Selek U
    J Geriatr Oncol; 2019 Jul; 10(4):567-572. PubMed ID: 31178158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study.
    Reboul F; Brewer Y; Vincent P; Chauvet B; Faure CF; Taulelle M
    Int J Radiat Oncol Biol Phys; 1996 May; 35(2):343-50. PubMed ID: 8635942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of oral glutamine supplementation on survival outcomes of patients treated with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer.
    Topkan E; Parlak C; Topuk S; Pehlivan B
    BMC Cancer; 2012 Oct; 12():502. PubMed ID: 23113946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and Impact of Pretreatment Tumor Cavitation on Survival Outcomes of Stage III Squamous Cell Lung Cancer Patients Treated With Radical Concurrent Chemoradiation Therapy.
    Topkan E; Selek U; Ozdemir Y; Yildirim BA; Guler OC; Ciner F; Besen AA; Findikcioglu A; Ozyilkan O
    Int J Radiat Oncol Biol Phys; 2018 Aug; 101(5):1123-1132. PubMed ID: 29887509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.
    Koo TR; Moon SH; Lim YJ; Kim JY; Kim Y; Kim TH; Cho KH; Han JY; Lee YJ; Yun T; Kim HT; Lee JS
    Radiat Oncol; 2014 Dec; 9():283. PubMed ID: 25498887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of aggressive concurrent radiochemotherapy in highly selected septuagenarians with stage IIIB non-small cell lung carcinoma: retrospective analysis of 89 patients.
    Topkan E; Parlak C; Topuk S; Guler OC; Selek U
    Lung Cancer; 2013 Aug; 81(2):226-30. PubMed ID: 23726526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Radiation Therapy Techniques on Outcome in N3-positive IIIB Non-small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy.
    Noh JM; Kim JM; Ahn YC; Pyo H; Kim B; Oh D; Ju SG; Kim JS; Shin JS; Hong CS; Park H; Lee E
    Cancer Res Treat; 2016 Jan; 48(1):106-14. PubMed ID: 25687865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoradiotherapy-induced hemoglobin nadir values and survival in patients with stage III non-small cell lung cancer.
    Topkan E; Selek U; Ozdemir Y; Yildirim BA; Guler OC; Mertsoylu H; Hahn SM
    Lung Cancer; 2018 Jul; 121():30-36. PubMed ID: 29858023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The addition of induction chemotherapy with etoposide, ifosfamide, and cisplatin failed to improve therapeutic outcome of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer -- single institution retrospective analysis.
    Lee HW; Choi JH; Lim HY; Park JS; Kim HC; Kang S; Oh YT; Chun M; Sheen SS; Oh YJ; Park KJ; Hwang SC
    Neoplasma; 2006; 53(1):30-6. PubMed ID: 16416010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer.
    Zhai Y; Ma H; Hui Z; Zhao L; Li D; Liang J; Wang X; Xu L; Chen B; Tang Y; Wu R; Xu Y; Pang Q; Chen M; Wang L
    Radiother Oncol; 2019 Feb; 131():27-34. PubMed ID: 30773184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer.
    Ercelep O; Alan O; Sahin D; Telli TA; Salva H; Tuylu TB; Babacan NA; Kaya S; Dane F; Ones T; Alkis H; Adli M; Yumuk F
    Clin Transl Oncol; 2019 Apr; 21(4):499-504. PubMed ID: 30229391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
    Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
    Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
    Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
    Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of different chemotherapy regimens for concurrent chemoradiotherapy on locally advanced non-small cell lung cancer].
    Ren H; Wang LH; Wang XZ; Lü JM; Ji W; Zhou ZM; Ou GF; Yin WB
    Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):143-7. PubMed ID: 19538894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
    Taugner J; Käsmann L; Karin M; Eze C; Flörsch B; Guggenberger J; Li M; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
    Invest New Drugs; 2022 Feb; 40(1):163-171. PubMed ID: 34351518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
    Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
    Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Definitive chemoradiotherapy in Stage III nonsmall cell lung cancer: Turkey experience.
    Yilmaz U; Yılmaz U; Yasar Z; Kıraklı EK; Ulger S; Ozdogan Y; Demirci NY; Erol S; Ozdogan I; Sahin B; Koksal D; Akcay C
    J Cancer Res Ther; 2016; 12(1):334-9. PubMed ID: 27072260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.